Trade Olema Pharmaceuticals, Inc. - OLMA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 9.81 |
| Open | 9.63 |
| 1-Year Change | 138.37% |
| Day's Range | 9.5 - 10.03 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 9.81 | 0.04 | 0.41% | 9.77 | 9.92 | 9.43 |
| Apr 24, 2024 | 10.12 | 0.25 | 2.53% | 9.87 | 10.14 | 9.85 |
| Apr 23, 2024 | 9.95 | 0.15 | 1.53% | 9.80 | 10.36 | 9.61 |
| Apr 22, 2024 | 9.83 | -0.15 | -1.50% | 9.98 | 10.09 | 9.72 |
| Apr 19, 2024 | 9.90 | 0.34 | 3.56% | 9.56 | 10.12 | 9.28 |
| Apr 18, 2024 | 9.87 | -0.72 | -6.80% | 10.59 | 10.59 | 9.74 |
| Apr 17, 2024 | 10.67 | -0.14 | -1.30% | 10.81 | 11.00 | 10.62 |
| Apr 16, 2024 | 10.77 | 0.10 | 0.94% | 10.67 | 10.94 | 10.55 |
| Apr 15, 2024 | 10.82 | 0.09 | 0.84% | 10.73 | 11.28 | 10.67 |
| Apr 12, 2024 | 10.83 | -0.50 | -4.41% | 11.33 | 11.66 | 10.61 |
| Apr 11, 2024 | 11.51 | 0.52 | 4.73% | 10.99 | 11.53 | 10.87 |
| Apr 10, 2024 | 10.91 | -0.18 | -1.62% | 11.09 | 11.18 | 10.80 |
| Apr 9, 2024 | 11.50 | 0.35 | 3.14% | 11.15 | 11.61 | 11.07 |
| Apr 8, 2024 | 11.24 | 0.36 | 3.31% | 10.88 | 11.27 | 10.65 |
| Apr 5, 2024 | 10.65 | -0.02 | -0.19% | 10.67 | 11.20 | 10.48 |
| Apr 4, 2024 | 10.47 | -0.61 | -5.51% | 11.08 | 11.12 | 10.35 |
| Apr 3, 2024 | 11.05 | 0.34 | 3.17% | 10.71 | 11.24 | 10.59 |
| Apr 2, 2024 | 10.79 | -0.52 | -4.60% | 11.31 | 11.31 | 10.64 |
| Apr 1, 2024 | 10.86 | -0.32 | -2.86% | 11.18 | 11.18 | 10.66 |
| Mar 28, 2024 | 11.29 | 0.30 | 2.73% | 10.99 | 11.45 | 10.75 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Olema Pharmaceuticals, Inc. Company profile
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It’s been ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Olema Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $24M to $71.1M. Higher net loss reflects Research and development increase from $11.7M to $41.8M (expense), Stock-based Compensation in R&D increase from $2M to $9.3M (expense), General and administrative - Balancing increase from $6.7M to $13.8M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
780 Brannan Street
SAN FRANCISCO
CALIFORNIA 94103
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com